RT @EpistemonikosEs: 🆕Revisión viva actualizada: Inhibidores de la IL-6 para el tratamiento de COVID‐19. Utilizando L.OVE, entre otras fuen…
🆕Revisión viva actualizada: Inhibidores de la IL-6 para el tratamiento de COVID‐19. Utilizando L.OVE, entre otras fuentes, la RS concluye un efecto beneficioso de #tocilizumab sobre la mortalidad a corto plazo en hospitalizados con #covid19 ➕ℹ️: https://t
RT @vimap2014: Inhibidores de la interleucina 6 para el tratamiento de la covid‐19: una revisión sistemática continua - Ghosn, L - 2021 | C…
Inhibidores de la interleucina 6 para el tratamiento de la covid‐19: una revisión sistemática continua - Ghosn, L - 2021 | Cochrane Library https://t.co/8kiJLWeOe1
トシリズマプ IL-6を阻害 https://t.co/xxq3e3BTJO
¿Pueden los medicamentos que bloquean la interleucina 6 (una proteína implicada en las respuestas inmunitarias) un bloqueo covid-19? #medicina #Salud https://t.co/kz4zH8dTlW
あ、あった。こういうのもちゃんとあるんだね。 „我々は、トシリズマブが28日時点での(あらゆる原因による)死亡者数を減少させたと確信している。“ https://t.co/6Ltl77jW8J
Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review - Ghosn, L - 2021 | Cochrane Library https://t.co/fziNJ2VX0i
RT @EcCochrane: La interleucina-6 es importante en la respuesta inmunológica contra #SARS_CoV_2 ¿Entonces los agentes que bloquean su act…
RT @EcCochrane: La interleucina-6 es importante en la respuesta inmunológica contra #SARS_CoV_2 ¿Entonces los agentes que bloquean su act…
RT @EcCochrane: La interleucina-6 es importante en la respuesta inmunológica contra #SARS_CoV_2 ¿Entonces los agentes que bloquean su act…
RT @EcCochrane: La interleucina-6 es importante en la respuesta inmunológica contra #SARS_CoV_2 ¿Entonces los agentes que bloquean su act…
RT @EcCochrane: La interleucina-6 es importante en la respuesta inmunológica contra #SARS_CoV_2 ¿Entonces los agentes que bloquean su act…
La interleucina-6 es importante en la respuesta inmunológica contra #SARS_CoV_2 ¿Entonces los agentes que bloquean su actividad podrían servir como tratamiento para #Covid_19? Te contamos en el resumen👉🏽https://t.co/S7qaHODVzg O en el estudio completo👉
RT @mintimetz: #CochraneReview Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review Published 18 March 2021.…
RT @EpistemonikosEs: También somos parte de la revisión Cochrane sobre este tema https://t.co/Dgxka3u22d de la revisión viva de la OPS htt…
We are also part of the teams that authored: the Cochrane review on this topic https://t.co/8lDCY8v0We the PAHO living review https://t.co/xpT5YGQ2vP and the COVID-NMA living review https://t.co/ul58It89NN
También somos parte de la revisión Cochrane sobre este tema https://t.co/Dgxka3u22d de la revisión viva de la OPS https://t.co/yOWpuzN7jL y de la revisión viva COVID-NMA https://t.co/MHF8sUcrIk
RT @Saber_IMSS: Conoce si los medicamentos que bloquean la #Interleucina6 pueden funcionar para combatir #COVID19, en el siguiente artículo…
RT @CochraneJapan: COVID19患者に対する IL-6阻害薬(主にトシリズマブ)の効果を検証したコクランレビューが出版されました。主に中等症以上の患者さんを組み入れた8本のRCTの結果からIL-6阻害薬は28日死亡を少し改善すると結論付けられました。未出版研…
#CochraneReview Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review Published 18 March 2021. (3/x) https://t.co/hZ93ZJkEaW https://t.co/b3PejIiEWR
RT @clinical_smart: Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review - Ghosn, L - 2021 | Cochrane Library ht…
RT @clinical_smart: Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review - Ghosn, L - 2021 | Cochrane Library ht…
RT @clinical_smart: Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review - Ghosn, L - 2021 | Cochrane Library ht…
RT @clinical_smart: Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review - Ghosn, L - 2021 | Cochrane Library ht…
Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review - Ghosn, L - 2021 | Cochrane Library https://t.co/zEl0hgioQU
Inhibidores de la interleucina 6 para el tratamiento de la covid‐19: una revisión sistemática continua - Ghosn, L - 2021 | Cochrane Library https://t.co/QS9lrs0cx6
①COVID19におけるトシリズマブのバイオマーカー評価の論文。medRxivへのprint掲載。 https://t.co/5ZKsgBEyCm 参考①サブ解析の対象となったRCT https://t.co/D1Sdd1Li5A 参考②COVID治療におけるトシリズマブの有用性についてのコクランレビュー https://t.co/14aquNVmkW
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
RT @PerlasClinicas: #Recomendado. Tocilizumab y reducción de mortalidad en #COVID-19 [https://t.co/EFJrrsyCfu]
Hola! Nos cuentan que este enlace funciona mejor https://t.co/JAqjv3OlLU
Avaliamos os efeitos (eficácia e segurança) dos agentes bloqueadores da IL‐6 versus cuidados padrão ou placebo em pacientes com COVID‐19. Veja na revisão sistemática: https://t.co/ly2UszyUQY https://t.co/jZwbfeOpMx
Inhibidores de la interleucina 6 para el tratamiento de la covid‐19: una revisión sistemática continua https://t.co/5T4LAyGisi https://t.co/1otBmz4nvI
RT @alfonso_casi: Revisión sistemática continua Cochrane, 18/3: Inhibidores de la interleucina 6 para el tratamiento de la covid‐19. https:…
RT @Links_Medicus: Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review – via @CochraneLibrary https://t.co/D4d…
RT @Links_Medicus: Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review – via @CochraneLibrary https://t.co/D4d…
RT @Links_Medicus: Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review – via @CochraneLibrary https://t.co/D4d…
Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review – via @CochraneLibrary https://t.co/D4dS2VZBqu
RT @alfonso_casi: Revisión sistemática continua Cochrane, 18/3: Inhibidores de la interleucina 6 para el tratamiento de la covid‐19. https:…
Revisión sistemática continua Cochrane, 18/3: Inhibidores de la interleucina 6 para el tratamiento de la covid‐19. https://t.co/gCW4Vy3rmP https://t.co/hFT6eXkBBg
Interleukin-6 blocking agents for treating COVID-19: a living systematic review - PubMed https://t.co/i16uApO7Oo
RT @CochraneUK: JUST PUBLISHED - Interleukin‐6 blocking agents for treating #COVID19 https://t.co/pt8BNfBwa3 New living systematic review f…
RT @CochraneUK: JUST PUBLISHED - Interleukin‐6 blocking agents for treating #COVID19 https://t.co/pt8BNfBwa3 New living systematic review f…
RT @CochraneUK: JUST PUBLISHED - Interleukin‐6 blocking agents for treating #COVID19 https://t.co/pt8BNfBwa3 New living systematic review f…
RT @CochraneUK: JUST PUBLISHED - Interleukin‐6 blocking agents for treating #COVID19 https://t.co/pt8BNfBwa3 New living systematic review f…
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
RT @EpistemonikosEs: Una nueva revisión sistemática #Living📄 sale a la luz gracias al trabajo colaborativo y nuestra Plataforma #L·OVE💚💪 ¡F…
RT @CochraneIreland: We are very happy to be a part of this @cochranecollab review w/ @CovidNma. The results show that treating #COVID19 wi…
New Cochrane Review: Can medicines that block interleukin-6 (a protein involved in immune responses) treat COVID-19? #COVID19dk #dkforsk #sundforsk https://t.co/wuQbA3JwXM @CovidNma @SUND_SDU
RT @CochraneJapan: インターロイキン6(免疫反応に関与するタンパク質)を阻害する薬でCOVID-19を治療できるか? https://t.co/x4woXsFpgf
インターロイキン6(免疫反応に関与するタンパク質)を阻害する薬でCOVID-19を治療できるか? | Cochrane https://t.co/QkEf8p0RFd
RT @GteiSemi: Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review - Ghosn, L - 2021 | Cochrane Library On aver…
インターロイキン6(免疫反応に関与するタンパク質)を阻害する薬でCOVID-19を治療できるか? https://t.co/x4woXsFpgf
RT @GteiSemi: Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review - Ghosn, L - 2021 | Cochrane Library On aver…
RT @dfviasusp: COVID19: tocilizumab reduces mortality at D28 compared to standard care alone or placebo and probably results in slightly fe…
RT @dfviasusp: COVID19: tocilizumab reduces mortality at D28 compared to standard care alone or placebo and probably results in slightly fe…
RT @dfviasusp: COVID19: tocilizumab reduces mortality at D28 compared to standard care alone or placebo and probably results in slightly fe…
RT @dfviasusp: COVID19: tocilizumab reduces mortality at D28 compared to standard care alone or placebo and probably results in slightly fe…
RT @dfviasusp: COVID19: tocilizumab reduces mortality at D28 compared to standard care alone or placebo and probably results in slightly fe…
COVID19: tocilizumab reduces mortality at D28 compared to standard care alone or placebo and probably results in slightly fewer serious adverse events. Nevertheless, tocilizumab probably results in little or no increase in the outcome clinical improvement
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
RT @GteiSemi: Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review - Ghosn, L - 2021 | Cochrane Library On aver…
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review - Ghosn, L - 2021 | Cochrane Library On average, tocilizumab reduces all‐cause mortality at D28 compared to standard care alone or placebo. https://t.co/i4jZKhIZmH
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
RT @CochraneJapan: COVID19患者に対する IL-6阻害薬(主にトシリズマブ)の効果を検証したコクランレビューが出版されました。主に中等症以上の患者さんを組み入れた8本のRCTの結果からIL-6阻害薬は28日死亡を少し改善すると結論付けられました。未出版研…
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
RT @NUIGalwayMed: Congratulations to @decdevane and colleagues @n_gnursing @hrbireland on this Cochrane review @cochranecollab
RT @CochraneJapan: COVID19患者に対する IL-6阻害薬(主にトシリズマブ)の効果を検証したコクランレビューが出版されました。主に中等症以上の患者さんを組み入れた8本のRCTの結果からIL-6阻害薬は28日死亡を少し改善すると結論付けられました。未出版研…
RT @CochraneJapan: COVID19患者に対する IL-6阻害薬(主にトシリズマブ)の効果を検証したコクランレビューが出版されました。主に中等症以上の患者さんを組み入れた8本のRCTの結果からIL-6阻害薬は28日死亡を少し改善すると結論付けられました。未出版研…
RT @CochraneJapan: COVID19患者に対する IL-6阻害薬(主にトシリズマブ)の効果を検証したコクランレビューが出版されました。主に中等症以上の患者さんを組み入れた8本のRCTの結果からIL-6阻害薬は28日死亡を少し改善すると結論付けられました。未出版研…
RT @CochraneJapan: COVID19患者に対する IL-6阻害薬(主にトシリズマブ)の効果を検証したコクランレビューが出版されました。主に中等症以上の患者さんを組み入れた8本のRCTの結果からIL-6阻害薬は28日死亡を少し改善すると結論付けられました。未出版研…
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
RT @CochraneJapan: COVID19患者に対する IL-6阻害薬(主にトシリズマブ)の効果を検証したコクランレビューが出版されました。主に中等症以上の患者さんを組み入れた8本のRCTの結果からIL-6阻害薬は28日死亡を少し改善すると結論付けられました。未出版研…
Congratulations to @decdevane and colleagues @n_gnursing @hrbireland on this Cochrane review @cochranecollab
RT @CochraneJapan: COVID19患者に対する IL-6阻害薬(主にトシリズマブ)の効果を検証したコクランレビューが出版されました。主に中等症以上の患者さんを組み入れた8本のRCTの結果からIL-6阻害薬は28日死亡を少し改善すると結論付けられました。未出版研…
RT @CochraneJapan: COVID19患者に対する IL-6阻害薬(主にトシリズマブ)の効果を検証したコクランレビューが出版されました。主に中等症以上の患者さんを組み入れた8本のRCTの結果からIL-6阻害薬は28日死亡を少し改善すると結論付けられました。未出版研…
COVID19患者に対する IL-6阻害薬(主にトシリズマブ)の効果を検証したコクランレビューが出版されました。主に中等症以上の患者さんを組み入れた8本のRCTの結果からIL-6阻害薬は28日死亡を少し改善すると結論付けられました。未出版研究は41本あり、結果が待たれます。 https://t.co/5E9V2z7XrT
RT @OrlandoRPN: Revision Cochrane de anti-IL6 (Tocilizumab), 10 estudios, casi 7,000 px, a favor de indicarlo por reducción de mortalidad a…
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
Likely controls cytokine hyper-reaction
RT @CovidNma: Are #tocilizumab and #sarilumab effective against COVID‐19? This is the research question addressed by our Cochrane Review on…
RT @OrlandoRPN: Revision Cochrane de anti-IL6 (Tocilizumab), 10 estudios, casi 7,000 px, a favor de indicarlo por reducción de mortalidad a…